A BILL 
To amend the Public Health Service Act to provide for 
stockpiles to ensure that all Americans have access to 
generic drugs at risk of shortage, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Essential Medicines 
4
Strategic Stockpile Act of 2020’’. 
5
00:44 Oct 29, 2020
H8479
2 
•HR 8479 IH
SEC. 2. PILOT PROGRAM ON ENSURING MEDICATION SUP-
1
PLY STABILITY. 
2
Part D of the Public Health Service Act (42 U.S.C. 
3
254b et seq.) is amended by adding at the end the fol-
4
lowing new subpart: 
5
‘‘Subpart XIII—Ensuring Medication Supply Stability 
6
‘‘SEC. 340J. ENSURING MEDICATION SUPPLY STABILITY. 
7
‘‘(a) AWARD OF CONTRACTS.—Beginning not later 
8
than January 1, 2021, the Secretary shall award contracts 
9
to eligible entities to each implement and test the effective-
10
ness of acquiring, maintaining, managing, and distrib-
11
uting a stockpile that— 
12
‘‘(1) consists of generic drugs at risk of short-
13
age; and 
14
‘‘(2) is of sufficient quantity to ensure that cus-
15
tomers in the United States of the respective eligible 
16
entity have access to such drugs for at least 6 
17
months (as specified by the Secretary based on the 
18
historic demand for those drugs). 
19
‘‘(b) SELECTION OF DRUGS.— 
20
‘‘(1) IN GENERAL.—The Secretary shall— 
21
‘‘(A) select not more than 50 types of 
22
drugs that may be included by eligible entities 
23
in a stockpile pursuant to a contract under this 
24
section; and 
25
00:44 Oct 29, 2020
H8479
3 
•HR 8479 IH
‘‘(B) maintain an up-to-date list of such 
1
drugs; and 
2
‘‘(C) make such list publicly available. 
3
‘‘(2) CHOICE OF ELIGIBLE ENTITIES.—A con-
4
tract awarded to an eligible entity under this section 
5
need not require the stockpile of the eligible entity 
6
to include all 50 types of drugs listed pursuant to 
7
paragraph (1). 
8
‘‘(c) SUFFICIENT QUANTITY.—For each generic drug 
9
in a stockpile maintained pursuant to subsection (a), the 
10
Secretary shall specify the quantity of such drug that is 
11
sufficient for purposes of such subsection to ensure that 
12
consumers in the United States of the respective eligible 
13
entity have access to such drug for at least 6 months. 
14
‘‘(d) DURATION; LIQUIDATION OF INVENTORY.— 
15
‘‘(1) DURATION.—A contract awarded under 
16
this section shall be for a term of no more than 3 
17
years. 
18
‘‘(2) LIQUIDATION
OF
INVENTORY.—A drug 
19
held in a stockpile pursuant to a contract under this 
20
section may be liquidated by the eligible entity at the 
21
end of the period of the contract. 
22
‘‘(e) STOCKPILE REQUIREMENTS.— 
23
‘‘(1) ENSURING AVAILABILITY OF UNEXPIRED 
24
PRODUCTS.—Each eligible entity with a contract 
25
00:44 Oct 29, 2020
H8479
4 
•HR 8479 IH
under this section for a stockpile of generic drugs at 
1
risk of shortage shall— 
2
‘‘(A) ensure that each drug maintained in 
3
the stockpile has an expiration date at least 1 
4
year beyond the current date; and 
5
‘‘(B) to comply with subparagraph (A)— 
6
‘‘(i) sell drugs in the stockpile through 
7
normal commercial channels and replace 
8
those drugs; or 
9
‘‘(ii) if there is no commercial market 
10
for a drug in the stockpile, dispose of the 
11
drug, report such disposal to the Secretary, 
12
and replace the drug. 
13
‘‘(2) MANAGEMENT OF STOCKPILE.— 
14
‘‘(A) IN
GENERAL.—Each eligible entity 
15
with a contract under this section for a stock-
16
pile of generic drugs at risk of shortage shall— 
17
‘‘(i) acquire not later than 6 months 
18
following the date the contract is awarded, 
19
and maintain thereafter, a 6-month supply 
20
of each type of drug the eligible entity has 
21
contracted to stockpile, which 6-month 
22
supply shall be in addition to the average 
23
levels of inventory held by such eligible en-
24
00:44 Oct 29, 2020
H8479
5 
•HR 8479 IH
tity over the previous year for such drug; 
1
and 
2
‘‘(ii) if it is not possible to comply 
3
with clause (i), notify the Secretary, citing 
4
the reason why it is not possible and the 
5
expected time of acquisition of the drug. 
6
‘‘(B) INVENTORY MANAGEMENT.—Each el-
7
igible entity with a contract under this section 
8
for a stockpile of generic drugs at risk of short-
9
age shall manage inventory to ensure that 
10
drugs in the stockpile are efficiently cycled to 
11
the commercial market and— 
12
‘‘(i) may stockpile inventory at the eli-
13
gible entity’s distribution center with speci-
14
fied inventory amounts virtually reserved 
15
for the Federal Government with constant 
16
cycling to reduce product expiration; or 
17
‘‘(ii) may store stockpiled inventory 
18
separately in a different location and re-
19
place drugs in the stockpile inventory with 
20
the same drug with newer dating. 
21
‘‘(C) INSUFFICIENT
FUNDS.—If amounts 
22
available to an eligible entity through contracts 
23
under this section are not sufficient to acquire 
24
or maintain a 6-month supply of any drug in 
25
00:44 Oct 29, 2020
H8479
6 
•HR 8479 IH
the stockpile of the eligible entity funded under 
1
this section, the eligible entity— 
2
‘‘(i) may acquire and maintain less 
3
than a 6-month supply, but in no case less 
4
than a 3-month supply; and 
5
‘‘(ii) shall submit a report to the Sec-
6
retary identifying— 
7
‘‘(I) each such drug; and 
8
‘‘(II) the reasons why such 
9
amounts are not sufficient to acquire 
10
or maintain a 6-month supply. 
11
‘‘(D) ANNUAL
AUDITS.—Not more than 
12
annually, the Secretary may request a physical 
13
audit count of the inventories of all eligible enti-
14
ties with a contract under this section to vali-
15
date that each such entity is maintaining the 
16
appropriate amount of stockpiled inventory. 
17
‘‘(3) PERIODIC PRODUCT REVIEW.— 
18
‘‘(A) USE OF PROCEEDS.—An eligible enti-
19
ty with a contract under this section for a 
20
stockpile of generic drugs at risk of shortage 
21
shall use the proceeds of the sale of any drugs 
22
in the stockpile to purchase drugs for the stock-
23
pile in accordance with this section. 
24
00:44 Oct 29, 2020
H8479
7 
•HR 8479 IH
‘‘(B) MARKET
INFLATION
OR
DEFLA-
1
TION.—In the case of market inflation or defla-
2
tion affecting the price of a drug in the stock-
3
pile of an eligible entity maintained pursuant to 
4
a contract under this section, the contract shall 
5
ensure that the Federal Government does not 
6
profit or suffer loss on items of such drug as 
7
a result of such inflation or deflation. 
8
‘‘(4) REPORTING.—Each eligible entity with a 
9
contract under this section shall submit reports at 
10
such time and in such manner as the Secretary may 
11
require regarding— 
12
‘‘(A) current inventory levels of stockpiled 
13
drugs at a drug level; 
14
‘‘(B) indicators of current inventory levels 
15
of stockpiled drugs relative to acceptable mini-
16
mums; and 
17
‘‘(C) such other matters as the Secretary 
18
determines appropriate. 
19
‘‘(f) CONTRACT TERMS.— 
20
‘‘(1) PAYMENT OF MONTHLY FEES FOR MAN-
21
AGEMENT.—Subject to paragraph (2), the Secretary 
22
shall pay to each eligible entity with a contract 
23
under this section for a stockpile of generic drugs at 
24
00:44 Oct 29, 2020
H8479
8 
•HR 8479 IH
risk of shortage appropriate monthly fees for the 
1
management of the stockpile. 
2
‘‘(2) PAYMENT
CONDITIONED
ON
STOCKPILE 
3
ADEQUACY.— 
4
‘‘(A) IN GENERAL.—Except as provided in 
5
subparagraph (B), each contract with an eligi-
6
ble entity under this section shall provide that 
7
no payment under the contract may be made 
8
until the entity demonstrates to the Secretary 
9
that the entity has stockpiled such portion of 
10
the total quantity of drugs to be stockpiled 
11
under the contract as the Secretary determines 
12
to be acceptable for payment. 
13
‘‘(B) EXCEPTIONS
FOR
ADVANCE
PAY-
14
MENTS.— 
15
‘‘(i) IN GENERAL.—A contract under 
16
this section may provide that, if the Sec-
17
retary determines (in the Secretary’s dis-
18
cretion) that an advance payment, partial 
19
payment for significant milestones, or pay-
20
ment to increase capacity is necessary to 
21
ensure success of the terms of the con-
22
tract, the Secretary shall pay, in advance 
23
of delivery, an amount not to exceed 10 
24
percent of the total contract amount to be 
25
00:44 Oct 29, 2020
H8479
9 
•HR 8479 IH
paid to the eligible entity by the Secretary 
1
pursuant to the contract over the full pe-
2
riod of the contract. 
3
‘‘(ii) COST OF CAPITAL.—A contract 
4
under this section may provide for pay-
5
ments to compensate the contracting eligi-
6
ble entity for additional capital require-
7
ments related to the additional inventory 
8
to be maintained. 
9
‘‘(iii) TIMING.—The Secretary shall, 
10
to the extent practicable, make any deter-
11
mination under clause (i) to make an ad-
12
vance payment at the same time as the 
13
issuance of a solicitation. 
14
‘‘(iv) REPAYMENT.—If the Secretary 
15
makes an advance payment pursuant to 
16
clause (i), the Secretary shall require the 
17
eligible entity receiving such advance pay-
18
ment to repay it if there is a failure to per-
19
form by the eligible entity. 
20
‘‘(3) TERMINATION.— 
21
‘‘(A) IN
GENERAL.—Subject to subpara-
22
graph (B), nothing in this section shall be con-
23
strued as affecting the rights of eligible entities 
24
under provisions of statute or regulation (in-
25
00:44 Oct 29, 2020
H8479
10 
•HR 8479 IH
cluding the Federal Acquisition Regulation) re-
1
lating to the termination of contracts for the 
2
convenience of the Government. 
3
‘‘(B) LIQUIDATION OF STOCKPILE.—If a 
4
contract under this section is terminated, the 
5
eligible entity with the contract shall liquidate 
6
the drugs comprising the stockpile funded 
7
through the contract and return to the Govern-
8
ment any amounts owed in relation to such 
9
drugs, but shall collect the management fees as-
10
sociated with such liquidation. 
11
‘‘(g) CONGRESSIONAL OVERSIGHT.— 
12
‘‘(1) INDEPENDENT
EVALUATION
AND
RE-
13
14
actment of this section and annually thereafter, the 
15
Comptroller General of the United States shall con-
16
duct an independent evaluation, and submit to the 
17
appropriate congressional committees a report, con-
18
cerning the program under this section. 
19
‘‘(2) CONTENTS OF REPORT.—The report under 
20
paragraph (1) shall review, assess, and provide rec-
21
ommendations, as appropriate, on the following: 
22
‘‘(A) Details on likely costs and resultant 
23
savings as compared to a stockpiling method 
24
00:44 Oct 29, 2020
H8479
11 
•HR 8479 IH
that does not incorporate perpetual inventory 
1
cycling. 
2
‘‘(B) Identification of drawdowns from the 
3
stockpile, as evidence of market shortage avoid-
4
ance. 
5
‘‘(C) The allocation of drugs included in 
6
the stockpiles funded pursuant to this section to 
7
the customers of the eligible entities with con-
8
tracts under this section. 
9
‘‘(D) The degree to which eligible entities 
10
with contracts under this section fulfilled their 
11
obligations under such contracts. 
12
‘‘(h) DEFINITIONS.—In this section: 
13
‘‘(1) The term ‘eligible entity’ means an entity 
14
that meets each of the following criteria: 
15
‘‘(A) The entity is licensed or registered in 
16
accordance with applicable Federal and State 
17
law and in good standing with respect to such 
18
licensure or registration. 
19
‘‘(B) The entity agrees— 
20
‘‘(i) to purchase all drugs to be main-
21
tained in its stockpile funded under this 
22
section directly from the manufacturers of 
23
the drugs or the exclusive distributors of 
24
such manufacturers; or 
25
00:44 Oct 29, 2020
H8479
12 
•HR 8479 IH
‘‘(ii) in the case of an entity that is a 
1
co-op or chain pharmacy warehouse— 
2
‘‘(I) to purchase drugs to be 
3
maintained in its stockpile funded 
4
under this section from an authorized 
5
distributor; and 
6
‘‘(II) distribute those drugs only 
7
to its member pharmacies. 
8
‘‘(C) The entity holds a verified authorized 
9
wholesale distributor certification issued by the 
10
National Association of Boards of Pharmacy. 
11
‘‘(D) The entity sells more than 90 percent 
12
of its drugs to dispensers. 
13
‘‘(E) The entity agrees to distribute inven-
14
tory from its stockpile funded under this section 
15
only to dispensers that are customers of the en-
16
tity. 
17
‘‘(2) The term ‘generic drug at risk of shortage’ 
18
means a drug (as defined in section 201 of the Fed-
19
eral Food, Drug, and Cosmetic Act) that— 
20
‘‘(A) is approved pursuant to section 
21
505(j) of such Act; 
22
‘‘(B) is included in the World Health Or-
23
ganization’s most recent Model List of Essen-
24
tial Medicines; 
25
00:44 Oct 29, 2020
H8479
13 
•HR 8479 IH
‘‘(C) is included, at any point during the 
1
preceding 36 months, on the drug shortage list 
2
in effect under section 506E of the Federal 
3
Food, Drug, and Cosmetic Act; and 
4
‘‘(D) is manufactured by 3 or fewer per-
5
sons that are registered under section 510 of 
6
the Federal Food, Drug, and Cosmetic Act for 
7
purposes of such manufacture. 
8
‘‘(i) AUTHORIZATION
OF
APPROPRIATIONS.—To 
9
carry out this section, there is authorized to be appro-
10
priated $120,000,000 for fiscal years 2021 through 2023, 
11
to remain available until expended.’’. 
12
Æ 
00:44 Oct 29, 2020
H8479
